Summary
The product Clomid 50mg, manufactured by Pharmago Labs, underwent independent testing to verify its authenticity and potency. The sample, submitted by the Manufacturer Pharmaqo Labs mrp@vitamins.to, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Clomiphene Citrate, with a concentration of 51.40 mg, exceeding the labeled claim of 50 mg by 2.8%.
The testing process began on 1 February 2024, with the analysis completed on the same day. While the results confirm accurate dosing, the batch number was not provided, and the sample description lacked detailed information. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Pharmaqo Labs
- Product Name: Clomid 50mg
- Active Ingredient: Clomiphene Citrate
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #38176
- Testing Ordered: 25 January 2024
- Sample Received: 31 January 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Pharmaqo Labs (Manufacturer)
- Analysis Paid For By: Pharmaqo Labs (Manufacturer)
Testing Results
- Specification: 50 mg (as stated on the label)
- Measured Concentration: 51.40 mg
- Accuracy: 102.8% (2.8% above the label claim)
- Variance: 2.8
Verification Details
- Verification URL: https://janoshik.com/tests/38176_PAF7DB8ZKE6E
Evaluation of Manufacturer-Submitted Testing
This analysis highlights the accuracy of the tested product but warrants careful evaluation due to the lack of detailed sample information and batch number. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results.
Conclusion
The analysis confirms that Clomid 50mg is slightly overdosed, with a measured concentration of 51.40 mg. This result reflects strong quality control for this sample but underscores the importance of additional testing and detailed sample information to ensure product consistency and reliability. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding post-cycle therapy (PCT) medications and related products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
